Director of the Centre for Liver and Gastrointestinal Research & Professor of Hepatology, University of Birmingham, and Consultant Hepatologist at the Liver Unit, Queen Elizabeth Hospital, Birmingham.
Director of the Centre for Liver and Gastrointestinal Research & Professor of Hepatology, University of Birmingham, and Consultant Hepatologist at the Liver Unit, Queen Elizabeth Hospital, Birmingham. He graduated from the Medical School at the University of Edinburgh in 1995 and moved to Birmingham in 2007.
He runs the metabolic services at the Liver Unit at the Queen Elizabeth Hospital Birmingham which includes a large multi-disciplinary clinic for patients with NAFLD. Professor Newsome has published over 100 research papers in scientific journals as well as many book chapters in the field of Non-Alcoholic Fatty Liver Disease (NAFLD). His laboratory group focusses on identifying novel targets in the pathogenesis of NAFLD and has access to in vivo methodologies in patients. He was Chief Investigator on a randomised controlled trial of Glucagon-like peptide-1 (GLP-1) therapy in NAFLD published in the Lancet, and is also Chief Investigator on a study of Fibroscan in NAFLD published in Gastroenterology. He is the Co-ordinating Investigator for several global NAFLD studies. He is editor of a recently published textbook on Liver Transplantation, chaired the national guidelines for liver transplantation in NAFLD and sat on the NICE Guideline Development Group for NAFLD. He led the recent UK multi-stakeholder guideline group on the management of abnormal liver blood tests.
He has a large laboratory group focussing on the role of cell therapy in liver injury. He has received a range of funding including large project/programme grants (EUFP7, MRC and MRC/Wellcome Clinical Training Fellowships). He has established two cutting edge clinical trials which he is the Chief Investigator on. One of these, REALISTIC, is the largest clinical trial of haematopoietic stem cell therapy in patients with liver cirrhosis in Europe/US was published in Lancet GastroHep. He co-ordinates the MERLIN (EU FP7) consortium which includes a clinical trial of mesenchymal stromal cells in patients with primary sclerosing cholangitis (PSC) and also the POLARISE basket trial in patients with PSC, rheumatoid arthritis, Crohn’s disease and lupus nephritis.
This research portfolio has led to high impact publications throughout including both original articles (PNAS, Gastroenterology, Journal of Hepatology, Hepatology, Nature, Gut, American Journal of Transplantation, Annals of Internal Medicine, Lancet) and review articles (FASEB, Nature Reviews, Gastroenterology, Journal of Hepatology).